Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) ...
The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...
Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented ...
Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome ...
Aumolertinib had comparable efficacy to osimertinib when treating epidermal growth factor receptor ( EGFR )-mutant non-small ...
Current treatment options for EGFR-mutant lung cancer include oral therapy combinations with chemotherapy and emerging ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...
In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in ...
MedPage Today on MSN
How Do GLP-1 Drugs Stack Up for Cardiorenal Benefits in Diabetes?
"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...
Hong Kong, Shanghai Tuesday, October 14, 2025, 11:00 Hrs [IST] ...
Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling a certain type of lung cancer, there’s good news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback